Merck Gets FDA OK For Expanded Pifeltro, Delstrigo Indications

Date : 09/20/2019 @ 12:52PM
Source : Dow Jones News
Stock : Merck and Co Inc (MRK)
Quote : 83.8  0.0 (0.00%) @ 11:04AM

Merck Gets FDA OK For Expanded Pifeltro, Delstrigo Indications

Merck (NYSE:MRK)
Historical Stock Chart

1 Month : From Sep 2019 to Oct 2019

Click Here for more Merck Charts.

By Colin Kellaher


Merck & Co. (MRK) on Friday said the U.S. Food and Drug Administration approved supplemental new-drug applications expanding the use of the HIV-1 treatments Pifeltro and Delstrigo.

The Kenilworth, N.J., drug maker said the approval expands the indications for Pifeltro, in combination with other antiretroviral agents, and Delstrigo as a complete regimen to include adults with HIV-1 infection who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to Pifeltro or the individual components of Delstrigo.

The FDA last year approved Pifeltro and Delstrigo for the treatment of HIV-1 infection in adults with no prior antiretroviral treatment history.


Write to Colin Kellaher at


(END) Dow Jones Newswires

September 20, 2019 07:37 ET (11:37 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest MRK Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.